about
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...
Read More
92.54
0.51
(0.55%)
1.7M
XNAS Volume
XNAS 13 Mar, 2026 5:30 PM (EDT)
Medium Financial Strength
Affordable Valuation
Technically Neutral
Mid-range Performer
These stocks have affordable valuations, but mid range financials and momentum
View Similar
Embed DVM
Incyte Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..